Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 38.5% in December

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 88,900 shares, a decrease of 38.5% from the November 30th total of 144,600 shares. Approximately 2.2% of the shares of the company are short sold. Based on an average daily volume of 1,760,000 shares, the short-interest ratio is currently 0.1 days.

Virax Biolabs Group Trading Up 0.6 %

VRAX stock opened at $1.73 on Friday. The stock has a fifty day moving average of $1.94 and a 200-day moving average of $2.06. Virax Biolabs Group has a fifty-two week low of $0.60 and a fifty-two week high of $9.00.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.